Obsidio, Inc. Awarded Prestigious Fast Track Small Business Innovation Research Grant by National Heart, Lung, and Blood Institute
COLUMBIA, S.C., July 13, 2021 /PRNewswire/ -- Obsidio, Inc., a privately held company developing minimally invasive embolic products for use in vascular embolotherapy, today announced it has been awarded a $2.1 million Fast Track Small Business Innovation Research (SBIR) grant from the National Heart, Lung, and Blood Institute (NHLBI).
- COLUMBIA, S.C., July 13, 2021 /PRNewswire/ -- Obsidio, Inc., a privately held company developing minimally invasive embolic products for use in vascular embolotherapy, today announced it has been awarded a $2.1 million Fast Track Small Business Innovation Research (SBIR) grant from the National Heart, Lung, and Blood Institute (NHLBI).
- Obsidio Inc. is a venture capital-funded medical device startup dedicated to the research, development, and commercialization of breakthrough embolotherapy products.
- http://obsidiomed.com
The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs are highly competitive programs that encourage domestic small businesses to engage in Federal Research/Research and Development (R/R&D) with the potential for commercialization. - By including qualified small businesses in the nation's R&D arena, high-tech innovation is stimulated, and the United States gains entrepreneurial spirit as it meets its specific research and development needs.